An outline of the most recent policy shared by the White House Tuesday night would empower Medicare to negotiate the cost for 10 of the most expensive drugs by 2025, and 20 drugs per year by 2028, while carving out exceptions for small biotech companies. Only drugs that have passed their initial exclusivity periods — 9 years on the market for some drugs and 12 for others — would be eligible for negotiation, and the government can use an excise tax to force pharmaceutical companies to the bargaining table.
Patents last 20 years, the approval process 10. Roughly, circa, you understand.
So all this shouting about being able to negotiate drug prices, it’s not about patented ones at all, it’s about generics? That is, not very much at all?